NCT05523206View on ClinicalTrials.gov

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

December 19, 2024

Study Completion Date

January 28, 2025

Conditions
Mucopolysaccharidosis III-A
Interventions
OTHER

No intervention

No intervention

Trial Locations (1)

01801

Sanguine Biosciences, Inc., Woburn

Sponsors

Collaborators (1)

Denali Therapeutics Inc.
All Listed Sponsors
collaborator

Denali Therapeutics Inc.

INDUSTRY

lead

Sanguine Biosciences

INDUSTRY

NCT05523206 - A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome) | Biotech Hunter | Biotech Hunter